A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
← catalyst calendarNCT07073547 · readout in 645 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-31 | actual | When the study began enrolling |
| Primary completion | 2028-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Biological: AZD0120
Primary outcomes
what the primary-completion date above is the date OFAdverse Events (AEs)
measured 2 years
Serious Adverse Events (SAEs)
measured 2 years
Dose Limiting Toxicities (DLT)
measured 28 days
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed